After $600 Million Typo, Valeant CEO Is Back on the Hot Seat

  • Conference call gets baffled, angry reaction from investors
  • Shares plunge the most ever as analysts question company chief

Valeant Suffers Biggest Drop on Record, What's Next?

Michael Pearson and his company, Valeant Pharmaceuticals International Inc., were supposed to calm Wall Street doubters on Tuesday. Instead: chaos.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.